Previous Close | 27.07 |
Open | 27.43 |
Bid | 26.88 x 1000 |
Ask | 28.10 x 1000 |
Day's Range | 26.45 - 27.66 |
52 Week Range | 11.70 - 33.80 |
Volume | |
Avg. Volume | 520,771 |
Market Cap | 714.013M |
Beta (5Y Monthly) | 2.61 |
PE Ratio (TTM) | 6.52 |
EPS (TTM) | 4.12 |
Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.79 |
SAN DIEGO, June 01, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
Celebrations may be in order for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, with the analysts...
Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades for Albemarle, Euronav, Arcturus Therapeutics, and Palo Alto Networks. KeyBanc upgraded Albemarle (NYSE:ALB) to Overweight from Sector Weight with a price target of $270, as reported in real time on InvestingPro. KeyBanc expects demand for lithium in China to improve after a downturn that started in November 2022, noting that its recent checks from the Li industry in China indicate that inventories at the battery cell/EV OEM level are declining, and could bottom out in the coming months.
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 09, 2023--Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings' (NASDAQ:ARCT) stock is up by a considerable 29% over the past three months. But the...
SAN DIEGO, April 26, 2023--Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shares have had a really impressive month, gaining 79% after a...
Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 25.9% higher as of 11:16 a.m. on Wednesday. The big gain came after the company provided its fourth-quarter update after the market closed on Tuesday. Fourth-quarter collaboration revenue was $160.3 million, up from $5.8 million in the prior-year period.
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, March 28, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2022, and provided corporate updates.
With the business potentially at an important milestone, we thought we'd take a closer look at Arcturus Therapeutics...
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
SAN DIEGO, March 07, 2023--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast
SAN DIEGO, February 06, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
SAN DIEGO, January 31, 2023--Arcturus Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders might be concerned after seeing the share price drop...
SAN DIEGO, December 19, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
SAN DIEGO, December 13, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Ma
Whilst it may not be a huge deal, we thought it was good to see that the Arcturus Therapeutics Holdings Inc...
The latest analyst coverage could presage a bad day for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ), with the...
Arcturus Therapeutics Holdings ( NASDAQ:ARCT ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.4m (up...
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, November 09, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", "Arcturus Therapeutics", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2022, and provided corporate updates.
SAN DIEGO, November 07, 2022--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.